NRG Meeting Banner for Website_NoReg

Welcome to NRG Oncology!

Welcome to the NRG Oncology Web site! This resource serves to provide current information about NRG Oncology’s exciting research future and the latest updates about plans to support our clinical trial endeavors. We invite you to check back often to learn “what’s new.”

About NRG Oncology

NRG Oncology brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon our more than 150 years of cumulative research experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer. NRG Oncology has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN).

Click here to access all weekly broadcasts

NCORP Badge English636404806468909532

NRG Oncology is proud to be an 
active participant of Cancer Moonshot.


Learn about the leaders and plans for NRG Oncology's NCORP Research Base.


NRG Oncology
Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103
Contact Us

To receive the NRG Oncology Newsletter and occasional eNews announcements and press releases, please email

What’s New

Due to inclement weather, the Biospecimen Banks request that you hold shipments of frozen specimens until the storms have passed. Fresh blood may be shipped as normal with extra insulation since specimens may be delayed in transit. Check for delays and weather alerts before you ship. (posted January 17, 2019)

Special Report: NRG Oncology Strategic Planning Retreat Debrief Read more

Time to Biochemical Failure Could be Used as a Surrogate Endpoint in Treatment of Locally Advanced Prostate Cancer Read more

Project Team Member Application - Hu5F9-G4 application forms due by COB January 4, 2019. Read more

NCTN and NCORP CIRB Requirement Policy: Implementation Date Effective March 1, 2019

NCI’s National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP) are implementing new requirements for membership in and use of the NCI Central IRB (CIRB). This policy is necessary to bring the NCTN and NCORP programs into compliance with the NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research (NOT-OD-16-094). This policy applies to all United States sites enrolling patients in NCTN and NCORP studies and all Groups and Research Bases funded through the NCTN and NCORP programs. As of March 1, 2019, all sites must be members of the NCI CIRB to enroll new patients on any NCTN or NCORP trials. On this date, sites that are not CIRB members will be put in a “suspended” status on the NCTN and NCORP membership rosters and will not be able to enroll new patients to NCTN and NCORP trials. Most NRG Oncology sites are already members of the NCI CIRB but if you are not sure please contact your local IRB. Read more

NRG/RTOG Application and Server Maintenance Friday, December 7th 6:00 PM until Monday, December 10th 8:00 AM. Read more

NRG-LU002 Webinar Recording and Materials are now posted. Also, register for the follow up "Ask the PI" Question and Answer webinar. Read more

Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed Glioblastoma Read more

Register today for the NRG-LU002 Webinar on November 29, 2018 Read more

NRG Oncology Newsletter Vol. 4 2018 is now available Read more

SBRT Considered Safe Treatment Option for Patients with Multiple (2-4) Metastases Read more

Combined therapy including pelvic lymph node radiation provides significant benefit for prostate cancer patients Read more

Radiation therapy outcomes better for African-American prostate cancer patients than Caucasian patients Read more

NRG-RTOG 9813 is the First Study to Identify the Impact of MGMT Gene Expression on Overall Survival for Patients with Anaplastic Glioma Tumors Read more

Short-Term Androgen-Deprivation Therapy with Radiotherapy Improves Survival over Radiotherapy Alone for up to 10 Years among Men with Early Stage Prostate Adenocarcinoma Read more

Patient Reported Outcomes on NRG-RTOG 0232 Indicate Brachytherapy Alone is the Superior Treatment for Men with Intermediate Risk Prostate Cancer Read more

Data Supports Interaction of Pretreatment Immune Inflammatory State of Patient Outcomes following Radiotherapy in High Risk Prostate Cancer Trial Read more

Applications for NRG Oncology Clinical Research Coordinator Mentor Program Now Open  Read More

The Addition of a CTLA4 Targeted Therapy to a PD-1 Targeted Therapy Could Benefit Women with Ovarian Cancer  Read more

Hurricane Florence Notice: Potential Impact on NRG Oncology Research
Hurricane Florence Notice: Potential Impact on NRG Oncology Research
Copyright 2019 by NRG Oncology